News

15

Oct. 2018

Invitation to Recipharm- Hadasit Event “From Molecule to Drug”
16

Aug. 2018

Hadasit Newsletter August 2018

Hadasit Newsletter JULY 2018 for Website
31

Jul. 2018

Antiseptic Materials Startup Nobio Raises $3.6 Million
30

May. 2018

From B2B: Hadasit conference , May 30, 2018
27

May. 2018

Recipharm and Hadasit partner to deliver seamless and clinical services
7

May. 2018

Hadassah doctors team up with Azrieli college engineers to co-develop medical devices
2

May. 2018

Biomed 2018 Conference – invitation : happy hour at Hadasit Booth
7

Mar. 2018

Immuron Reports Positive Results in NASH Clinical Trial

Oral IMM-124E Significantly Reduces LPS, a Major Factor in Liver Inflammation
7

Mar. 2018

BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, today announced that the independent Data Safety Monitoring Board (DSMB) has approved initiation of the fourth cohort for the ongoing OpRegen® clinical trial.
28

Feb. 2018

Hadasit Newsletter February 2018

1
2

Quick Contact